HC Wainwright restated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a research report released on Friday morning, Benzinga reports. The firm currently has a $15.00 price objective on the stock. Other equities analysts have also recently issued research reports about the stock. Wedbush reiterated an outperform rating and issued […]

Related Keywords

, Lighthouse Investment Partners , Financial Perspectives Inc , Werewolf Therapeutics Inc , Acadian Asset Management , Denali Advisors , Werewolf Therapeutics Company Profile , Werewolf Therapeutics , Free Report , Get Free Report , Perspectives Inc , Investment Partners , Asset Management , Werewolf Therapeutics Daily ,